REVIEW ARTICLE

A Review of Pathophysiology, Clinical Manifestations, And Therapeutic Management of Methemoglobinemia

Ramya Sri Bura*[1], Sujatha Gorle[1], Gayathri Devi Setti[1], Ravi Prakash Degala[2]

[1]*PharmD Scholar, Department of Pharmacy Practice, Koringa College of Pharmacy, Korangi, Andhra Pradesh, India*
[2]*Associate Professor and HOD, Department of Pharmacy Practice, Koringa College of Pharmacy, Korangi, Andhra Pradesh, India*

Publication history: Received on 27th Dec 2024; Revised on 1st Jan 2025; Accepted on 6th Jan 2025

Article DOI: 10.69613/410fsd85

Abstract: Methemoglobinemia occurs when hemoglobin's iron is oxidized from ferrous (Fe2+) to ferric (Fe3+) state, resulting in impaired oxygen transport and potential tissue hypoxia. The condition manifests through inherited mutations affecting hemoglobin structure or enzymatic pathways, or through acquired causes including exposure to oxidizing agents and medications. Clinical presentations range from asymptomatic cases to severe manifestations like cyanosis, dyspnea, and life-threatening complications. Diagnostic challenges arise from the condition's ability to interfere with standard pulse oximetry readings, making specialized techniques like co-oximetry essential for accurate assessment. The primary therapeutic intervention involves methylene blue administration, which functions through the NADPH-dependent pathway to reduce methemoglobin levels. Treatment protocols require careful consideration of severity, underlying etiology, and individual patient factors, particularly G6PD status. Additional therapeutic options include ascorbic acid supplementation and supportive care measures. Recent molecular studies have enhanced the identification of genetic variants and improved understanding of drug-induced cases, leading to more targeted therapeutic approaches. Prevention strategies focus on identifying high-risk medications and environmental exposures. Early recognition and prompt intervention remain crucial for optimal patient outcomes, particularly in severe cases where methemoglobin levels exceed 30%.

Keywords: Methemoglobinemia; Oxidative Stress; Methylene Blue Therapy; Hemoglobin Disorders; Tissue Hypoxia.

1. Introduction

Methemoglobinemia represents a significant hematological disorder characterized by the presence of elevated levels of methemoglobin in the blood [1]. The oxidation of ferrous iron (Fe^{2+}) to ferric iron (Fe^{3+}) within the hemoglobin molecule fundamentally alters its oxygen-carrying capacity, potentially leading to severe tissue hypoxia [2]. Under normal physiological conditions, protective mechanisms maintain methemoglobin levels below 1% of total hemoglobin, primarily through the action of cytochrome b5 reductase [3].



Figure 1. Molecular structure comparison of normal hemoglobin and methemoglobin showing the iron oxidation state

The clinical significance of methemoglobinemia lies in its varied presentation and potential severity. While mild cases may present with minimal symptoms, severe cases can lead to life-threatening complications, particularly when methemoglobin levels exceed 50% [4]. The condition's importance in clinical practice has grown with the increasing recognition of its iatrogenic causes, particularly medication-induced cases [5].

* Corresponding author: Ramya Sri Bura

2. Pathophysiology

The formation of methemoglobin involves complex biochemical processes centered on hemoglobin oxidation. In normal erythrocytes, iron exists in the ferrous state, allowing optimal oxygen binding and release. When oxidative stress exceeds the cellular reduction capacity, iron oxidation occurs, forming methemoglobin [6].

Several protective mechanisms exist:

2.1. NADH-Cytochrome b5 Reductase System

The primary defense mechanism accounts for approximately 99% of methemoglobin reduction under normal conditions. This enzyme system converts methemoglobin back to functional hemoglobin using NADH as a cofactor [7].



Figure 2. NADH-Cytochrome b5 Reductase System

2.2. NADPH-Methemoglobin Reductase System

This secondary pathway, though normally contributing only 1% of reduction capacity, becomes crucial in therapeutic interventions, particularly when methylene blue is administered [8].

3. Etiology

Methemoglobinemia manifests in both inherited and acquired forms:

3.1. Inherited Forms

3.1.1. Hemoglobin M Disease

Results from genetic mutations in globin genes, creating structurally abnormal hemoglobin variants with increased susceptibility to oxidation [9].

3.1.2. Cytochrome b5 Reductase Deficiency

Presents in two types:

- Type I: Limited to erythrocytes
- Type II: Affects all body tissues, leading to more severe manifestations [10]

3.2. Acquired Forms

The most common form occurs through exposure to oxidizing agents, including:

- Medications:
- Local anesthetics (benzocaine, prilocaine)
- Antimalarials
- Antibiotics (dapsone, sulfonamides)
- Environmental exposures:

- Nitrates in well water
- Industrial chemicals
- Certain foods

Table 1. Common oxidizing agents associated with acquired methemoglobinemia

Category	Specific Agents	Route of Exposure	Risk Level	Common Setting
Local Anesthetics	Benzocaine Lidocaine Prilocaine EMLA cream	Topical Mucosal Spray Dental applications	High	Medical procedures Dental procedures Emergency departments Endoscopy suites
Antibiotics/Antimicrobials	Dapsone Sulfonamides Chloroquine Nitrofurantoin	Oral Intravenous	Moderate to High	Outpatient clinics Hospitals Long-term care facilities
Industrial Chemicals	Aniline dyes Nitrobenzene Naphthalene Aminophenols	Inhalation Dermal contact Occupational exposure	Very High	Chemical plants Dye manufacturing Industrial facilities Textile mills
Nitrates/Nitrites	Sodium nitrite Amyl nitrite Potassium nitrite Silver nitrate	Ingestion Inhalation Environmental exposure	High	Food processing Agriculture Well water contamination Recreational drug use
Household Products	Hair dyes Shoe polish Cleaning agents Herbicides	Dermal contact Accidental ingestion Household exposure	Moderate	Domestic settings Hair salons Cleaning services

4. Clinical manifestations

The clinical presentation of methemoglobinemia varies significantly, with symptoms directly correlating to methemoglobin levels and individual patient factors. Central cyanosis, particularly evident in the lips, nail beds, and mucous membranes, often serves as the earliest clinical indicator. This characteristic chocolate-brown cyanosis notably persists despite oxygen supplementation [18].

Symptom progression correlates with increasing methemoglobin levels, following a predictable pattern:

At levels between 10-20%, patients typically experience mild symptoms including skin color changes and occasional headaches. As levels rise to 20-30%, patients develop fatigue, dizziness, and anxiety. Methemoglobin concentrations of 30-50% lead to significant tachycardia, dyspnea, and confusion. Levels exceeding 50% may result in seizures, arrhythmias, and profound acidosis. Concentrations above 70% frequently prove fatal without immediate intervention [19].

Cardiovascular manifestations include tachycardia, hypotension, and in severe cases, dysrhythmias. These symptoms result from both direct tissue hypoxia and compensatory mechanisms attempting to maintain adequate oxygen delivery [20].

Table 2. Correlation between methemoglobin levels and clinical symptoms

Neurological manifestations progress from mild headaches and dizziness to altered mental status, seizures, and coma in severe cases. The central nervous system proves particularly vulnerable to hypoxic injury, making early recognition and intervention crucial [21].

Special consideration must be given to specific patient populations:

Neonates and infants demonstrate increased susceptibility due to lower levels of protective enzymes and fetal hemoglobin, which oxidizes more readily than adult hemoglobin [22].

Elderly patients often experience more severe manifestations due to comorbid conditions and reduced physiological reserves [23].

Patients with underlying cardiopulmonary disease show decreased tolerance to even modest elevations in methemoglobin levels [24].

The temporal relationship between exposure to oxidizing agents and symptom onset varies depending on the causative agent. Local anesthetics typically induce symptoms within minutes to hours, while other agents like dapsone may cause delayed presentation due to metabolic activation [25].

Laboratory findings often reveal normal arterial oxygen tension despite significant hypoxemia, creating a characteristic "saturation gap" between arterial blood gas analysis and pulse oximetry readings. This discrepancy serves as an important diagnostic clue [26].

5. Diagnosis

The diagnosis of methemoglobinemia relies on a combination of clinical suspicion, history, and specialized laboratory testing. The cornerstone of diagnosis centers on co-oximetry analysis, which provides direct measurement of methemoglobin levels through spectrophotometric analysis [27].

Initial diagnostic considerations should include:

- History of exposure to oxidizing agents, medications, or chemicals
- Presence of unexplained cyanosis unresponsive to oxygen therapy
- Discrepancy between pulse oximetry readings and clinical status [28]

5.1. Laboratory Assessment

Co-oximetry remains the gold standard for diagnosis. This method distinguishes between different hemoglobin species through multiple wavelength spectrophotometry. Standard pulse oximetry proves unreliable as it cannot differentiate between oxyhemoglobin and methemoglobin [29].

Arterial blood gas analysis typically shows a normal PaO_2 with decreased oxygen saturation, creating the characteristic "saturation gap." This gap represents the difference between the calculated and measured oxygen saturations [30].

5.2. Additional Testing

- Complete blood count to assess for concurrent anemia
- Basic metabolic panel to evaluate acid-base status
- Glucose-6-phosphate dehydrogenase (G6PD) levels prior to methylene blue administration
- Genetic testing in suspected hereditary cases [31]

5.3. Differential Diagnosis

The differential diagnosis includes:

- Sulfhemoglobinemia
- Carboxyhemoglobinemia
- Congenital heart disease with right-to-left shunting
- Polycythemia [32]

Point-of-care testing capabilities have expanded diagnostic options, allowing rapid identification in emergency settings. However, these results should be confirmed with formal laboratory testing when possible [33]. The diagnostic process must also include evaluation for underlying conditions or exposures that might predispose to recurrent episodes. This becomes particularly important in cases without clear precipitating factors [34].

6. Treatment and management

The management of methemoglobinemia follows a stepwise approach based on methemoglobin levels, symptom severity, and underlying causes. Immediate discontinuation of any identified oxidizing agent serves as the initial crucial step in management [35].

6.1. Therapeutic Intervention Levels

Asymptomatic patients with levels below 20% generally require only supportive care and monitoring. However, methemoglobin levels above 20%, or lower levels with significant symptoms, warrant specific therapeutic intervention [36].

6.1.1. First-Line Treatment

Methylene blue remains the definitive treatment, administered intravenously at 1-2 mg/kg over 5 minutes. This agent acts as an artificial electron carrier, enhancing the NADPH-dependent pathway of methemoglobin reduction. Treatment response typically manifests within one hour, with significant improvement in symptoms and methemoglobin levels [37].

Table 2. Clinical Management Based on Methemoglobin Levels

MetHb Level (%)	Clinical Manifestations	Management Approach	Treatment Priority
0-3 (Normal)	None	No treatment needed	Routine monitoring
3-15	Mild cyanosis, often asymptomatic	Identify and remove cause Observation	Non-urgent
15-30	Cyanosis Chocolate-brown blood Mild symptoms	Oxygen therapy Consider methylene blue if symptomatic	Urgent
30-50	Dyspnea Headache Fatigue Tachycardia	Immediate methylene blue (1-2 mg/kg IV) Intensive monitoring	Emergency
50-70	Mental status changes Seizures Arrhythmias Acidosis	Multiple doses of methylene blue Consider exchange transfusion ICU admission	Critical
>70	Severe hypoxic symptoms Death	Immediate intensive intervention Multiple therapeutic modalities Mechanical ventilation	Life-threatening

6.1.2. Important Contraindications

Methylene blue should be avoided in:

- G6PD deficiency due to risk of hemolysis
- Patients taking serotonergic medications due to risk of serotonin syndrome
- Severe renal impairment requiring dose adjustment [38]

6.1.3. Alternative Treatments

When methylene blue is contraindicated or ineffective, alternative options include:

- Ascorbic acid (Vitamin C) at high doses (1-2 g intravenously)
- N-acetylcysteine in selected cases

Exchange transfusion for severe cases unresponsive to other treatments [39]

6.1.4. Supportive Care

- Oxygen supplementation should be provided despite its limited efficacy in improving oxygen delivery
- Hemodynamic support as needed
- Close monitoring of cardiac and neurological status
- Management of any underlying acidosis [40]

6.2. Monitoring and Follow-up

- Serial measurement of methemoglobin levels
- Continuous pulse oximetry monitoring
- Assessment of end-organ function
- Evaluation for recurrence risk [41]

6.3. Prevention Strategies

- Implementation of medication protocols to prevent inadvertent exposure
- Genetic counseling for hereditary cases
- Education regarding environmental and occupational exposures
- Regular monitoring in patients requiring chronic therapy with high-risk medications [42]

6.4. Special Considerations

- Pediatric patients require careful dose adjustment of methylene blue
- Pregnant patients need individualized risk-benefit assessment
- Chronic cases may require prophylactic interventions [43].

7. Prognosis and complications

The prognosis of methemoglobinemia largely depends on several key factors: the initial methemoglobin level, duration of exposure, promptness of recognition and treatment, and underlying patient comorbidities [44].

7.1. Prognostic Factors

Favorable prognostic indicators include:

- Early recognition and treatment
- Rapid identification of causative agents
- Normal baseline organ function
- Appropriate response to initial therapy [45]

Poor prognostic factors include:

- Delayed presentation
- Multiple organ dysfunction
- Chronic high-level exposure
- Underlying cardiovascular disease [46]

7.2. Complications

7.2.1. Acute Complications

- Myocardial ischemia
- Neurological injury
- Metabolic acidosis
- Acute kidney injury
- Death in severe untreated cases [47]

7.2.2. Long-term Complications

- Cognitive deficits following severe episodes
- Cardiac remodeling in chronic cases
- End-organ damage from prolonged hypoxia
- Development of chronic anemia
- Psychological sequelae [48]

7.3. Risk Stratification

7.3.1. Low Risk

- Methemoglobin levels <20%
- No significant comorbidities
- Known reversible cause

7.3.2. Intermediate Risk

- Levels 20-40%
- Presence of cardiovascular disease
- Delayed presentation

7.3.3. High Risk:

- Levels >40%
- Multiple organ dysfunction
- Unknown etiology [49]

7.4. Recovery Patterns

- Most acute cases show complete recovery within 24-48 hours of appropriate treatment
- Chronic cases may require ongoing management and monitoring
- Some patients may develop increased susceptibility to future oxidative stress [50]

7.5. Quality of Life Impact

Acute episodes may result in:

1. Temporary work disability
2. Anxiety about recurrence
3. Need for medication modifications
4. Lifestyle adjustments [51]

7.6. Prevention of Recurrence:

1. Development of personalized prevention strategies
2. Regular monitoring in susceptible individuals
3. Medication review and adjustment
4. Occupational modification if necessary [52]

8. Conclusion

Methemoglobinemia remains a significant clinical entity requiring prompt recognition and intervention. The condition's diverse etiology, ranging from genetic predisposition to environmental exposures, necessitates a thorough understanding of its pathophysiology and management. Early recognition of clinical signs, particularly unexplained cyanosis unresponsive to oxygen therapy, is crucial for favorable outcomes. While methylene blue serves as the cornerstone of treatment, individualized approaches considering patient-specific factors are essential.

References

[1] Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management. South Med J. 2011;104(11):757-61.

[2] Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004;83(5):265-73.

[3] Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999;34(5):646-56.

[4] do Nascimento TS, Pereira RO, de Mello HL, Costa J. Methemoglobinemia: from diagnosis to treatment. Rev Bras Anestesiol. 2008;58(6):651-64.

[5] Umbreit J. Methemoglobin--it's not just blue: a concise review. Am J Hematol. 2007;82(2):134-44.

[6] Price D. Methemoglobinemia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

[7] Curry S. Methemoglobinemia. Ann Emerg Med. 1982;11(4):214-21.

[8] Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996;14(6):394-405.

[9] Cortazzo JA, Lichtman AD. Methemoglobinemia: a review and recommendations for management. J Cardiothorac Vasc Anesth. 2014;28(4):1043-7.

[10] Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol. 1993;42(1):7-12.

[11] Tejesh CA, Shivanna S, Manjunath AC, Prathima PT. ICU management of methemoglobinemia due to unknown compound poisoning. J Anaesthesiol Clin Pharmacol. 2013;29(1):139-40.

[12] Haymond S, Cariappa R, Eby CS, Scott MG. Laboratory assessment of oxygenation in methemoglobinemia. Clin Chem. 2005;51(2):434-44.

[13] Sharma VK, Haber AD. Acquired methemoglobinemia: a case report of benzocaine-induced methemoglobinemia and a review of the literature. Clin Pulm Med. 2002;9(1):53-8.

[14] Rehman HU. Methemoglobinemia. West J Med. 2001;175(3):193-6.

[15] Alanazi MQ. Drugs may be Induced Methemoglobinemia. J Hematol Thrombo Dis. 2017;5:270.

[16] Kaplan JC, Chirouze M. Therapy of recessive congenital methaemoglobinaemia by oral riboflavine. Lancet. 1978;2(8098):1043-4.

[17] Denshaw-Burke M, Schoffstall J. Methemoglobinemia. Medscape. 2021.

[18] Harvey JW, Keitt AS. Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinaemia. Br J Haematol. 1983;54(1):29-41.

[19] Toker I, Yesilaras M, Tur FC, Toktas R. Methemoglobinemia caused by dapsone overdose: Which treatment is best? Turk J Emerg Med. 2016;15(4):182-4.

[20] Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management. South Med J. 2011;104(11):757-61.

[21] Agarwal N, Nagel RL, Prchal JT. Dyshemoglobinemias. In: Williams Hematology. 8th ed. McGraw-Hill; 2010:699-707.

[22] Percy MJ, Lappin TR. Recessive congenital methaemoglobinaemia: cytochrome b5 reductase deficiency. Br J Haematol. 2008;141(3):298-308.

[23] Goldstein GM, Doull J. Treatment of nitrite-induced methemoglobinemia with hyperbaric oxygen. Proc Soc Exp Biol Med. 1971;138(1):137-9.

[24] Kus T, Aktas G, Topcu TO. Methemoglobinemia caused by lidocaine administration: a case report. Istanbul Med J. 2014;15(4):229-31.

[25] Bradberry SM. Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev. 2003;22(1):13-27.

[26] Gharahbaghian L, Massoudian B, Dimassa G. Methemoglobinemia and sulfhemoglobinemia in two pediatric patients after ingestion of hydroxylamine sulfate. West J Emerg Med. 2009;10(3):197-201.

[27] Marks MI, Alexander ER, Adimora AA. Methemoglobinemia associated with dapsone treatment of pemphigus. J Am Acad Dermatol. 1982;6(6):1084-6.

[28] Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004;83(5):265-73.

[29] Finkelstein Y, Vardi J. Progressive parkinsonism in a young experimental physicist following long-term exposure to methyl bromide. Neurotoxicology. 2002;23(4-5):521-5.

[30] Khanal R, Karmacharya P, Pathak R, et al. Do all patients with acquired methemoglobinemia need treatment? A lesson learnt. J Community Hosp Intern Med Perspect. 2015;5(5):29079.

[31] Krafte-Jacobs B, Brilli R, Szabo C, Denenberg A, Moore L, Salzman AL. Circulating methemoglobin and nitrite/nitrate concentrations as indicators of nitric oxide overproduction in critically ill children with septic shock. Crit Care Med. 1997;25(9):1588-93.

[32] Malhotra R, Hughes G. Methaemoglobinaemia presents as acute severe hypoxia. Emerg Med J. 2010;27(4):328-9.

[33] Kern K, Langevin PB. Methemoglobinemia after topical anesthetic-induced cyanosis. Anesth Analg. 2000;91(5):1290-1.

[34] Sharma VK, Haber AD. Acquired methemoglobinemia: a case report of benzocaine-induced methemoglobinemia and a review of the literature. Clin Pulm Med. 2002;9(1):53-8.

[35] Karadsheh NS, Shaker Q, Ratroat B. Methaemoglobinemia caused by topical benzocaine use for teething pain in a toddler. BMJ Case Rep. 2013;2013:bcr2013010321.

[36] Trapp L, Will J. Acquired methemoglobinemia revisited. Dent Clin North Am. 2010;54(4):665-75.

[37] Hunter L, Gordge L, Dargan PI, Wood DM. Methaemoglobinaemia associated with the use of cocaine and volatile nitrites as recreational drugs: a review. Br J Clin Pharmacol. 2011;72(1):18-26.

[38] Ward KE, McCarthy MW. Dapsone-induced methemoglobinemia. Ann Pharmacother. 1998;32(5):549-53.

[39] Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg. 2009;108(3):837-45.

[40] Nabukeera-Barungi N, Mworozi E. Sudden onset methaemoglobinaemia in a previously well Ugandan child: a case report and literature review. Pan Afr Med J. 2012;11:49.

[41] Jaffé ER, Hultquist DE. Cytochrome b5 reductase deficiency and enzymopenic hereditary methemoglobinemia. In: The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2001:4555-70.

[42] Singh H, Purnell E, Smith C. Mechanistic study on aniline-induced erythrocyte toxicity. Arch Toxicol. 2007;81(3):165-77.

[43] Wilkerson RG. Getting the blues at a rock concert: a case of severe methaemoglobinaemia. Emerg Med Australas. 2010;22(5):466-9.

[44] Chan TY. Food-borne nitrates and nitrites as a cause of methemoglobinemia. Southeast Asian J Trop Med Public Health. 1996;27(1):189-92.

[45] Barker SJ, Tremper KK, Hyatt J. Effects of methemoglobinemia on pulse oximetry and mixed venous oximetry. Anesthesiology. 1989;70(1):112-7.

[46] Daly JS, Hultquist DE, Rucknagel DL. Clinical and enzymatic heterogeneity associated with hereditary methemoglobinemia. J Clin Invest. 1967;46(11):1654-62.

[47] Herman MI, Chyka PA, Butler AY, Rieger SE. Methylene blue by intraosseous infusion for methemoglobinemia. Ann Emerg Med. 1999;33(1):111-3.

[48] Price DP, Sikora KA. The use of methylene blue in the treatment of methemoglobinemia: a systematic review. J Pharm Pract. 2017;30(4):431-8.

[49] Sheehan HE, Boon RJ. Methemoglobinemia from dapsone medical prophylaxis. Mil Med. 1983;148(5):414-5.

[50] Tötaro A, Rosato E, Di Paolo M, et al. Acquired methemoglobinemia: a retrospective study of 44 patients. Intern Emerg Med. 2021;16(4):967-73.

[51] Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med. 1986;314(12):757-61.

[52] Moore TJ, Walsh CS, Cohen MR. Reported adverse event cases of methemoglobinemia associated with benzocaine products. Arch Intern Med. 2004;164(11):1192-6.